ClinicalTrials.gg
CompletedNCT04060758Updated Nov 20, 2025

Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma

A Phase 1 interventional study of PA5108 Latanoprost FA SR Ocular Implant in Open Angle Glaucoma, sponsored by PolyActiva Pty Ltd. Completed at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by PolyActiva Pty Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Glaucoma, Open-Angle with a site in Australia — none open to participants now, 2 under way, none of them phase 3. Glaucoma, Open-Angle · Australia.

Enrollment
10th of 14
37 · median 84
Started
2020
the only one that year
Phase 1
4 of 14
none open now
Registered
9th of 14
by date
Lead sponsor
3 of 14
PolyActiva Pty Ltd

Among the 14 studies in Glaucoma, Open-Angle with a site in Australia, this one is the 10th largest by enrollment, is the only one that started in 2020, is one of 4 in phase 1, and was the 9th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

None of the 14 studies in Glaucoma, Open-Angle with a site in Australia is open now. The open studies under Glaucoma, Open-Angle, anywhere →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Glaucoma, Open-Angle with a site in Australia as a file.
02

Study summary

This is a multi-centre, open label, interventional, comparative, phase I study to identify a safe and efficacious dose (within the range of 14.7mcg to 35.5 mcg) of PA5108 (PolyActiva product code) Latanoprost free acid (FA) sustained release (SR) Ocular Implant in adults who have Primary Open Angle Glaucoma.

Read the detailed description

This is a multi-centre, open label, interventional, comparative, phase Ib dose ranging study to identify a safe and efficacious dose (within the range of 14.7 to 35.5 microgram) of PA5108 Latanoprost FA SR Ocular Implant in adults who have Primary Open Angle Glaucoma (POAG).

The proposed study is a single ascending dose design to determine the minimum effective dose that provides the target of >20% IOP lowering effect at 12 weeks with minimal adverse events.

Up to three single-dose cohorts will be assessed from the following implant strengths:

  • 35.5 microgram
  • 26.6 microgram
  • 14.7 microgram

In addition, a repeat-dose cohort will be assessed from the following implant strength:

o 14.7 microgram

A first cohort of participants will be recruited and dosed with the 14.7 mcg PA5108 Latanoprost FA SR Ocular Implant. A second cohort of participants will be recruited after SMC review of 6-week data of the first cohort and dosed with the 26.6 mcg PA5108 Latanoprost FA SR Ocular Implant. A third cohort of participants will be recruited after SMC review of 6-week data of the second cohort and repeat-dosed with 14.7 mcg PA5108 Latanoprost FA SR Ocular Implant. A fourth cohort of participants will be recruited and dosed with the 35.5 mcg PA5108 Latanoprost FA SR Ocular Implant

Prior to study registration, participants will have been medicated with intraocular pressure (IOP) lowering drop therapy, including a prostaglandin analogue, to manage their POAG. The IOP lowering drops will be stopped in the intent to treat eye within 29 to 43 days prior to the date of implant administration. Participants will be required to have an unmedicated (post wash-out) 8:00am IOP ≥ 24 mmHg and ≤ 36mmHg in the intent to treat eye at either of two screening visits 2-weeks apart. Additionally, the IOP at 12:00 noon and 4:00 pm must be ≥ 20mmHg and ≤ 36mmHg on the same screening visit where the 8:00am IOP was ≥ 24 mmHg and ≤ 36mmHg.

The PA5108 Latanoprost FA SR Ocular Implant will be administered to one eye (unilateral) of each participant.

IOP will be monitored and if after implant administration is found to rise ≥30% over baseline in the study eye, IOP lowering eye drops will be restarted.

The study will recruit up to 10 participants per cohort/dose level. After screening, eligible participants enrolled in the single-dose cohorts will be administered a single PA5108 Latanoprost FA SR Ocular Implant by clear corneal injection to the anterior chamber of the eye, by means of a custom-built injector fitted with a 27G pre-loaded needle at Day 0. Whereas eligible participants enrolled in the repeat-dose cohort will be administered a single PA5108 Latanoprost FA SR Ocular Implant by clear corneal injection to the anterior chamber of the eye, by means of a custom-built injector fitted with a 27G pre-loaded needle at Day 0, and again at Week 21.

The study will end at the later of Visit 12 (48-weeks) for the last participant in the repeat dose cohort, or when the last of the study implants are no longer visible in the study eye and the IOP in the same eye has returned to a normal clinical care range, or 12-weeks has passed since the implant was no longer visible regardless of IOP.

Participants in the single dose cohorts will attend the study site for follow up on Day 1 post implant administration, and then Week 6, 12, (optionally 15), 18, (optionally 21), 26, 32 and if required subsequent 6-week intervals until the implant has completely biodegraded and the IOP of the same eye has returned to normal clinical care range or 12-weeks has passed since the implant was no longer visible. Implant biodegradation will be confirmed by biomicroscopy and gonioscopy examination at Week 6, 12, optionally 15, 18, optionally 21, 26 \& 32, and if necessary, every 6-weeks thereafter.

Participants in the repeat dose cohort will attend the study site for follow up on Day 1 post implant administration, and then Week 6, 12,18, Week 21 (when they will be administered the second dose), Day 1 post repeat dose, Week 27, 33, 42, 48 and if required subsequent 6-week intervals until the implant has completely biodegraded and the IOP of the same eye has returned to normal clinical care range or 12-weeks has passed since the implant was no longer visible. Implant biodegradation will be confirmed by biomicroscopy and gonioscopy examination at Week 6,12,18, 21,27, 33,42 \& 48, and if necessary, every 6-weeks thereafter.

03

Conditions studied

  • Open Angle Glaucoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants who:

  • Diagnosis of primary open angle glaucoma.
  • Unmedicated 8:00am IOP ≥ 24 mmHg and ≤ 36mmHg in the intent to treat eye. Additionally, the IOP at 12:00 and 16:00 hrs must be ≥ 20mmHg and ≤ 36mmHg.
  • Corrected visual acuity in each eye greater than or equal to +0.3logMAR.
  • Minimum central endothelial cell density of greater than or equal to 1600 cells per mm2
  • Currently managing their POAG with IOP lowering drop therapy.

Exclusion criteria

Exclusion Criteria:

Participants who:

  • Have pseudoexfoliation or pigment dispersion component, history of angle closure, or narrow angles.
  • Have a history of or current ocular inflammation.
  • Have aphakic eyes or only one eye.
  • Recent surgery in the study eye surgery (including laser).
  • ocular disease in either eye (e.g., corneal oedema, uveitis, severe keratoconjunctivitis sicca or infection) which might interfere with the study.
  • Known sensitivity to any component of the product (e.g. latanoprost or polytriazole sensitivity), or to topical therapy used during course of study (e.g. povidone iodine, or anaesthetics).
  • Ocular medication in either eye of any kind within 30 days of screening.
  • Central corneal thickness in either eye that is less than 470 µm or greater than 630 µm at screening (or a difference between the eyes >70 µm).
  • Any abnormality in either eye preventing reliable applanation tonometry, including aphakic eyes or significant corneal guttatae.
  • Any other clinically significant disease (as determined by physician) which might interfere with the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    14.7 mcg (single dose)

    PA5108 Latanoprost FA SR Ocular Implant which releases 14.7 mcg.

    Drug: PA5108 Latanoprost FA SR Ocular Implant

  • Experimental
    26.6 mcg (single dose)

    PA5108 Latanoprost FA SR Ocular Implant which releases 26.6 mcg.

    Drug: PA5108 Latanoprost FA SR Ocular Implant

  • Experimental
    35.5 mcg (single dose)

    PA5108 Latanoprost FA SR Ocular Implant which releases 35.5 mcg.

    Drug: PA5108 Latanoprost FA SR Ocular Implant

  • Experimental
    14.7 mcg (repeat dose)

    Repeat dose of PA5108 Latanoprost FA SR Ocular Implant which releases 14.7 mcg.

    Drug: PA5108 Latanoprost FA SR Ocular Implant

Interventions

06

What researchers measure

Primary outcomes

  1. Effective dose

    Determine the minimum effective dose (as daily release rate of LtpFA) that achieves an IOP lowering effect \>20% with minimal adverse events.

    Time frame: Intraocular Pressure (IOP) change measured at; baseline, week 12 and week 26.

  2. Safety and Tolerability-incidence of treatment emergent Adverse Events

    Assess the safety and tolerability of PA5108 Latanoprost FA SR Ocular Implant in adults with Open Angle Glaucoma (Primary). Incidence of Treatment-Emergent Adverse Events from visit 1 until end of study. Safety laboratory evaluations (biochemistry, haematology, urinalysis). Physical examinations and vital signs. Changes in ocular examinations from baseline to end of study.

    Time frame: Incidence of Treatment-Emergent Adverse Events throughout the study (up to 1 year).

Secondary outcomes

  1. Ease of Use

    Assess the ease of use of the bespoke administration device- Administering ophthalmologist's assessment of ease of use of the bespoke administration device, verbal communication.

    Time frame: At visit 2-Day 0, after use of device to insert the implant into the eye.

07

Study locations

9 sites
  • PersonalEYES
    Castle Hill, New South Wales 2150, Australia
  • Goodwood Eye Centre
    Millswood, South Australia 5034, Australia
  • Bendigo Eye Clinic
    Bendigo, Victoria 3550, Australia
  • Centre for Eye Research Australia
    East Melbourne, Victoria 3002, Australia
  • Essendon Eye Clinic
    Essendon, Victoria 3040, Australia
  • Melbourne Eye Specialists
    Fitzroy, Victoria 3065, Australia
  • Eyes First
    Springvale, Victoria 3171, Australia
  • Eye Surgery Associates
    Vermont South, Victoria 3133, Australia
  • Capital Eye Specialists
    Te Aro, 6011, New Zealand
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in May 2025, 62 months.

Of 17 phase 1 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 23. This study's 62 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2019
First posted
Aug 19, 2019
StartActual
Mar 11, 2020
Primary completionActual
May 13, 2025
CompletionActual
May 13, 2025
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04060758
Lead sponsor
PolyActiva Pty Ltd
Responsible party
Sponsor
First posted
Aug 19, 2019
Start date
Mar 11, 2020
Primary completion
May 13, 2025
Completion
May 13, 2025
Last update
Nov 20, 2025

Study contacts

Michael Coote
principal investigator · Melbourne Eye Specialists

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PA5108

Start the discussion